ADXS - Advaxis updates early stage results for off-the-shelf immunotherapy with Keytruda in lung cancer

Advaxis (ADXS) released updated data from an ongoing Phase 1/2 trial for its off-the-shelf immunotherapy ADXS-503 in combination with Merck’s KEYTRUDA (pembrolizumab) in patients with metastatic non-small-cell lung cancer ((NSCLC)).The results will be part of a poster presentation at the upcoming American Society of Clinical Oncology ((ASCO)) 2021 Annual Meeting.After 10 patients were treated with ADXS-503 as an add-on therapy to those who failed pembrolizumab, all 10 patients were evaluable for safety and nine patients were evaluable for efficacy.The combination was well tolerated, the company said adding that Grade 1 and 2 adverse events, namely chills, fever, fatigue, seen in nearly half of the patients were transient and reversible.The Disease Control Rate ((DCR)) stood at 44% (4/9) with a durable clinical benefit, according to Advaxis. The observed partial response ((PR)) and stable disease ((SD)) has lasted for over a year, another SD was sustained for six months and a PR was maintained

For further details see:

Advaxis updates early stage results for off-the-shelf immunotherapy with Keytruda in lung cancer